Cystitis - Pipeline Insight, 2024

This “Cystitis- Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cystitis Understanding

Cystitis: Overview

Cystitis refers to infection of the lower urinary tract, or more specifically the urinary bladder. It may be broadly categorized as either complicated or uncomplicated (simple). Uncomplicated cystitis refers to a lower urinary tract infection (UTI) in either men or non-pregnant women who are otherwise healthy. Complicated cystitis, on the other hand, is associated with risk factors that increase the likelihood and danger of the infection or the chances of failing antibiotic therapy. Acute cystitis is typically caused by a bacterial infection of the urinary bladder. Escherichia coli is the most common etiologic agent in uncomplicated UTI in women, accounting for approximately 75% to 95% of cases. Cystitis usually develops due to the colonization of the periurethral mucosa by bacteria from the fecal or vaginal flora and the ascension of such pathogens to the urinary bladder. The leading symptoms of Cystitis are dysuria, frequency, urgency, and, occasionally, suprapubic pain. However, these symptoms are nonspecific and may also be associated with infection of the lower genitourinary tract (urethra, vagina) or with noninfectious conditions such as bladder carcinoma, urethral diverticulum, and calculi. There are a few different ways to diagnose cystitis. The doctor may ask for a urine sample to determine the cause of cystitis and check for a UTI. Doctor may also perform cystoscopy, or an imaging test to determine the cause of symptoms. Cystoscopy (In a cystoscopy, a doctor inspects bladder with a thin tube that has a camera and light attached. Doctors can use the cystoscope to collect a biopsy of bladder tissue if needed. A biopsy is a small tissue sample used for further testing) and Imaging test (Imaging tests are not often necessary, but they can be helpful in diagnosing cystitis. An X-ray or ultrasound can help rule out other causes of cystitis, such as a structural issue or tumor). Antibiotics are a common treatment for bacterial cystitis. Interstitial cystitis can also be treated with medication. Medication for interstitial cystitis depends on its cause. Surgery can treat cystitis, but it may not be the doctor’s first choice. It is more common for chronic conditions.

Cystitis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cystitis pipeline landscape is provided which includes the disease overview and Cystitis treatment guidelines. The assessment part of the report embraces, in depth Cystitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cystitis R&D. The therapies under development are focused on novel approaches to treat/improve Cystitis.

Cystitis Emerging Drugs Chapters

This segment of the Cystitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cystitis Emerging Drugs

SI 722: Seikagaku Corporation SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku's proprietary glycosaminoglycan modification technology and drug delivery systems. While a Phase I/II clinical trial in the U.S. experienced delays in the trial schedule due to the spread of COVID-19, subject enrollment was completed in January 2021, and tolerability in the patients of this trial has been confirmed. Currently, Seikagaku Corporation is exploring the next phase of trials based on the dataobtained.

Tacrolimus liposomal : Lipella Pharmaceuticals Lipella Pharmaceuticals, lead product, LP-10 for hemorrhagic cystitis is currently in a phase-2, multi-center clinical trial. Lipella has received US-FDA Orphan Designation for this developmental product.

Posoleucel: AlloVir Posoleucel is designed to play an important role in providing bridging immunity between conditioning and reconstitution of their immune systems. Restoring immunity during this time of severe immune compromise, posoleucel may substantially reduce or prevent virus-associated morbidity and mortality, and dramatically improve patient outcomes. Currently, the drug is in Phase II stage of development for the treatment of HemorrhagicCystitis.

Cystitis: Therapeutic Assessment

This segment of the report provides insights about the different Cystitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cystitis

There are approx. 15+ key companies which are developing the therapies for Cystitis. The companies which have their Cystitis drug candidates in the most advanced stage, i.e. Phase II include, AlloVir.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cystitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cystitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystitis drugs.

Cystitis Report Insights

• Cystitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cystitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cystitis drugs?
• How many Cystitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cystitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cystitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cystitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Seikagaku Corporation
• Lipella Pharmaceuticals
• AlloVir
• Ironwood Pharmaceuticals
• Paratek Pharmaceuticals
• Alivio Therapeutics
• Vaneltix Pharma
• Qu Biologics
• Imbrium Therapeutics
• MIRAE CELL BIO

Key Products

• SI 722
• Tacrolimus liposomal
• Posoleucel
• IW-3300
• Omadacycline
• IMB 150
• VNX 002
• QBECP
• Sunobinop
• MR-MC-01

This product will be delivered within 1-3 business days.